Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00007597

Trial Description

start of 1:1-Block title

Title

An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
subjects with advanced prostate carcinoma, when administered as two injections six months
apart.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was
established to provide a vanguard of the first 30 subjects who will have more frequent
monitoring of their safety. If safety is established, the remainder of the subjects will be
entered into the clinical study (i.e., Part II). All subjects will be males with advanced
prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all
will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007597
  •   2015/10/29
  •   2014/09/01
  •   [---]*
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2013-001790-25 
  •   NCT02234115  (ClinicalTrials.gov)
  •   FP01C-13-001  (Foreseeacer Pharmaceuticals, Inc.)
  •   2013-001790-25 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Prostatic Neoplasms
  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Leuprolide Mesylate
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Efficacy of Leuprolide Mesylate (LMIS 50mg); time frame: 336 days; The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) by Day 28 ± 1(day) following the first injection of LMIS 50 mg and the percentage of subjects with serum testosterone suppression (≤ 50 ng/dL) from Day 28 through Day 336 (remaining duration of the study).

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Post-suppression excursions of serum testosterone; time frame: 336 days; The proportion of subjects exhibiting post-suppression excursions of serum testosterone to >50 ng/dL, either through "breakthrough" (i.e., episodes unrelated to LMIS 50 mg dosing), or through the "acute-on-chronic" phenomenon (i.e., related to the second dose of LMIS 50 mg); Effect of LMIS 50 mg on serum PSA levels; and Effect of LMIS 50 mg on serum LH levels
- Pharmacokinetics of Leuprolide Mesylate (LMIS 50mg); time frame: Days 0, 1, 2, 3, 7, 14, 21, 28, 56, 84, 112, 140, 168, 169, 170, 171, 196, 224, 252,280, 308, 336; Plasma leuprolide concentrations (ng/mL) in PK population
- Safety and tolerability of LMIS 50 mg; time frame: 336 days; Determining the safety and tolerability of LMIS 50 mg based on adverse events (AEs), local tolerability, vital signs, electrocardiograms (ECGs), and clinical parameters

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Austria
  •   Czech Republic
  •   Germany
  •   Lithuania
  •   Poland
  •   Slovakia
  •   Taiwan, Province of China
  •   United States
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2014/08/31
  •   130
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Males aged ≥ 18 years old

2. Males with histologically confirmed carcinoma of the prostate

3. Subjects who are judged by the attending physician and/or Principal Investigator to
be a candidate for androgen ablation therapy

4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit

5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2

6. Life expectancy of at least 18 months

7. Laboratory values

- Absolute neutrophil count ≥ 1,500 cells/µL

- Platelets ≥ 100,000 cells/µL

- Hemoglobin ≥ 10 gm/dL

- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

- AST (SGOT) ≤ 2.5 × ULN

- ALT (SGPT) ≤ 2.5 × ULN

- Serum creatinine ≤ 1.5 mg/dL

- Lipid profile within acceptable range according to investigator's judgment

- HgbA1c within acceptable range according to investigator's judgment

- Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to
investigator's judgment

- Serum glucose within acceptable range according to investigator's judgement

- Urinalysis within normal range according to the investigator's judgment

8. Agree to use male contraceptive methods during study trial

9. Based on the Investigator's judgment, the ability to understand the nature of the
study and any hazards of participation, and to communicate satisfactorily with the
Investigator and to participate in, and to comply with, the requirements of the
entire protocol

10. All aspects of the protocol explained and written informed consent obtained

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen
therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of
carcinoma of the prostate. Radiation for pain control will be allowed during the
study.

- Receipt of any vaccination (including influenza) within 4 weeks of Baseline

- History of blood donation within 2 months of Baseline

- History of anaphylaxis to any LH-RH analogues

- Receipt of any LHRH suppressive therapy within 6 months of Baseline

- Major surgery, including any prostatic surgery, within 4 weeks of Baseline

- History and concomitant clinical and radiographic evidence of central nervous
system/spinal cord metastases. Subjects at risk for spinal cord compression will be
excluded.

- Clinical evidence of active urinary tract obstruction and subjects at risk for
urinary obstruction

- History of bilateral orchiectomy, adrenalectomy, or hypophysectomy

- History or presence of hypogonadism, or receipt of exogenous testosterone
supplementation within 6 months of Baseline

- Clinically significant abnormal ECG and/or history of clinically significant
cardiovascular disease as judged by the investigator

- History of drug and/or alcohol abuse within 6 months of Baseline

- Contraindication to leuprolide or an LHRH agonist as indicated on package labeling

- Use of 5-alpha reductase inhibitor within the last 6 months of Baseline

- History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well
controlled diabetes mellitus Type II will be allowed

- Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens

- Use of any investigational agent within 4 weeks of Baseline

- Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for
those listed in the permitted Concomitant Treatment section.

- Uncontrolled intercurrent illness that would jeopardize the subject's safety,
interfere with the objectives of the protocol, or limit the subject's compliance with
study requirements, as determined by the Investigator in consultation with the
Sponsor

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Foresee Pharmaceuticals Co., Ltd.
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • QPS-Qualitix
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Foresee Pharmaceuticals Co., Ltd.
    • John Mao, PhD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Foresee Pharmaceuticals Co., Ltd.
    • John Mao, PhD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   2
  •   2016/01/14


* This entry means the parameter is not applicable or has not been set.